NCT02394730 - Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

January 31, 2018

Conditions

HIV

Interventions

DRUG

vorapaxar

2.5mg of vorapaxar taken orally once daily for 12 weeks

DRUG

Placebo

Sugar pill taken orally once daily for 12 weeks

Trial Locations (7)

St Vincent's Hospital, Darlinghurst

Taylor Square Private Clinic, Darlinghurst

Melbourne Sexual Health Centre, Carlton

Northside Clinic, Fitzroy North

Monash Medical Centre, Melbourne

Georgetown University Hospital, Georgetown

Hennepin County Medical Centre, Minneapolis